Citations

Clear

141 citation(s) found for "Slack, S".

The Hartford Impact on the Care of Older Adults in Transition
Holland, Diane E. , Popejoy, Lori

Mayo Clinic

Journal of Gerontological Nursing | December 9, 2011 | Volume: 37 | Issue: 12 | Pages: 12-13

10.3928/00989134-20111104-03 | PMID 22148845 Get It

Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group
Tallman, Martin S. , Montesinos, Pau , Appelbaum, Frederick R. , Serna, Javier de la , Bennett, John M. , Debén, Guillermo, Bloomfield, Clara D. , González, José D. , Feusner, James H., González, Marcos , Gallagher, Robert E. , Miguel, José D. González‐San, Larson, Richard A. , Paietta, Elisabeth , Rayón, Chelo, Rowe, Jacob M. , Rivas, Concha, Schiffer, Charles A. , Vellenga, Edo , Shepherd, Lois E. , Slack, James L., Wiernik, Peter H. , Sanz, Miguel Á. , Kim, Haesook T. , Milone, Giuseppe , Willman, Cheryl L. , Larson, Richard A , Montesinos, Pau

Mayo Clinic

Blood | September 22, 2010 | Volume: 116 | Issue: 25 | Pages: 5650-5659

10.1182/blood-2010-06-288613 | PMID 20858857 Get It

Abstract Few studies have examined the outcome of large numbers of patients with the microgranular variant (M3V) of acute promyelocytic leukemia (APL) in the all-trans retinoic acid era. Here, the outcome of 155 patients treated with all-trans retinoic acid–based therapy on 3 clinical trials, North American Intergroup protocol I0129 and Programa para el Estudio de la Terapéutica en Hemopatía Maligna protocols LPA96 and LPA99, are reported. The complete remission rate for all 155 patients was 82%, compared with 89% for 748 patients with classical M3 disease. The incidence of the APL differentiation syndrome was 26%, compared with 25% for classical M3 patients, and the early death rate was 13.6% compared with 8.4% for patients with classical M3 morphology. With a median follow-up time among survivors of 7.6 years (range 3.6-14.5), the 5-year overall survival, disease-free survival, and cumulative incidence of relapse for patients with M3V were 70%, 73%, and 24%, respectively. With a median follow-up time among survivors of 7.6 years (range 0.6-14.3), the 5-year overall survival, disease-free survival, and cumulative incidence of relapse among patients with classical M3 morphology were 80% (P = .006 compared with M3V), 81% (P = .07), and 15% (P = .005), respectively. When outcomes were adjusted for the white blood cell count or the relapse risk score, none of these outcomes were significantly different between patients with M3V and classical M3 APL.
Pleural Effusions: Etiology, Diagnosis, and Management
Cordes, Mary Ellen

Mayo Clinic

The Journal of Continuing Education in Nursing | June 18, 2009 | Volume: 40 | Issue: 6 | Pages: 248-249

10.3928/00220124-20090522-03 | PMID 19639912 Get It

This column describes the etiology, diagnosis, and management of pleural effusions. J Contin Educ Nurs 2009;40(6):248–249.
Multicenter Study of Decitabine Administered Daily for 5 Days Every 4 Weeks to Adults With Myelodysplastic Syndromes: The Alternative Dosing for Outpatient Treatment (ADOPT) Trial
Steensma, David P. , Baer, Maria R. , Slack, James L., Buckstein, Rena , Godley, Lucy A. , Garcia‐Manero, Guillermo , Albitar, Maher , Larsen, Julie S., Arora, Sujata, Cullen, Michael, Kantarjian, Hagop M. , Godley, Lucy A , Steensma, David P , Kantarjian, Hagop

Mayo Clinic

Journal of Clinical Oncology | June 16, 2009 | Volume: 27 | Issue: 23 | Pages: 3842-3848

10.1200/jco.2008.19.6550 | PMID 19528372 Get It

Purpose Decitabine, a DNA-targeted hypomethylating agent, is approved by the United States Food and Drug Administration for treatment of patients with myelodysplastic syndromes (MDS) on a schedule of 15 mg/m2 administered via intravenous (IV) infusion every 8 hours for 3 days. This study assessed the efficacy and safety of an alternative dosing regimen administered on an outpatient basis in academic and community-based practices. Patients and Methods Patients were treated with decitabine 20 mg/m2 by IV infusion daily for 5 consecutive days every 4 weeks. Eligible patients were ≥ 18 years of age and had MDS (de novo or secondary) of any French-American-British (FAB) subtype and an International Prognostic Scoring System (IPSS) score ≥ 0.5. The primary end point was the overall response rate (ORR) by International Working Group (IWG 2006) criteria; secondary end points included cytogenetic responses, hematologic improvement (HI), response duration, survival, and safety. Results Ninety-nine patients were enrolled; the ORR was 32% (17 complete responses [CR] plus 15 marrow CRs [mCRs]), and the overall improvement rate was 51%, which included 18% HI. Similar response rates were observed in all FAB subtypes and IPSS risk categories. Among patients who improved, 82% demonstrated responses by the end of cycle 2. Among 33 patients assessable for a cytogenetic response, 17 (52%) experienced cytogenetic CR (n = 11) or partial response (n = 6). Conclusion Decitabine given on a 5-day schedule provided meaningful clinical benefit for patients with MDS, with more than half demonstrating improvement. This suggests that decitabine can be administered in an outpatient setting with comparable efficacy and safety to the United States Food and Drug Administration–approved inpatient regimen.
Left Ventricular Assist Device Therapy for Treatment of End-Stage Heart Failure
Seelandt, Katherine K., Farnsworth, Monica M.

Mayo Clinic

The Journal of Continuing Education in Nursing | May 28, 2009 | Volume: 40 | Issue: 4 | Pages: 150-151

10.3928/00220124-20090401-04 | PMID 19418752 Get It

Heart failure is a growing concern in health care today. Treatment options for end-stage heart failure include providing for optimal medical management or heart transplant. A left ventricular assist device may augment medical management and act as a bridge to transplant or lifetime therapy to promote quality of life. J Contin Educ Nurs 2009;40(4):150–151.
Symptom Check: Is It GERD?
Sveen, Stephanie

Mayo Clinic

The Journal of Continuing Education in Nursing | April 20, 2009 | Volume: 40 | Issue: 3 | Pages: 103-104

10.3928/00220124-20090301-04 | PMID 19326815 Get It

Despite the vast number of individuals living with gastroesophageal reflux disease (GERD), establishing a diagnosis can be difficult. Detailed patient history and symptom review are critical. Nurses can play an integral role in gathering information that may lead to a definitive diagnosis. In addition to the classic symptoms of GERD—acid reflux and heartburn—several atypical conditions may also be present. Understanding the diverse and subtle nature of presenting symptoms can assist in establishing a GERD diagnosis. This column examines the atypical presentations of GERD, including laryngopharyngeal symptoms, chronic cough, asthma, and dental erosions. J Contin Educ Nurs 2009;40(3):103–104.
Nurses Built the Hospital: A Readers' Theater Used in Nursing Orientation
Pestka, Elizabeth L.

Mayo Clinic

The Journal of Continuing Education in Nursing | April 20, 2009 | Volume: 40 | Issue: 3 | Pages: 105-106

10.3928/00220124-20090301-11 | PMID 19326816 Get It

The nursing profession has a long history of helping to advance health care. This column describes contributions of the first nurses associated with a major medical center in the Midwest and their vision to build and staff a hospital to support the medical practice of a local physician and his two sons. The story comes to life as a readers' theater featured in department-wide orientation to the Department of Nursing. J Contin Educ Nurs 2009;40(3):105–106.
Duty to Care
Pfrimmer, Dale M.

Mayo Clinic

The Journal of Continuing Education in Nursing | April 20, 2009 | Volume: 40 | Issue: 2 | Pages: 53-54

10.3928/00220124-20090201-04 | PMID 19263924 Get It

The potential threat of a pandemic influenza outbreak has placed emergency preparedness in the health care spotlight. Hospitals are increasingly gearing up readiness plans in preparation. Most of these plans are related to the implementation of protocols and stockpiling of supplies, medications, and equipment. These plans are dependent on staff for implementation, but will nurses' duty to care for patients outweigh their competing obligations to their families and the risk of their own exposure? J Contin Educ Nurs 2009;40(2):53–54.
Newer Antidepressants and Gabapentin for Hot Flashes: An Individual Patient Pooled Analysis
Loprinzi, Charles L. , Sloan, Jeff A. , Slack, Rebecca, Iyengar, Malini, Diekmann, Brent, Kimmick, Gretchen , Lovato, James , Gordon, Paul , Pandya, Kishan J., Guttuso, Thomas , Barton, Debra L. , Novotny, Paul J. , Stearns, Vered

Mayo Clinic

Journal of Clinical Oncology | March 31, 2009 | Volume: 27 | Issue: 17 | Pages: 2831-2837

10.1200/jco.2008.19.6253 | PMID 19332723 Get It

Purpose Nonhormonal treatment options have been investigated as treatments for hot flashes, a major clinical problem in many women. Starting in 2000, a series of 10 individual double-blind placebo-controlled studies has evaluated newer antidepressants and gabapentin for treating hot flashes. This current project was developed to conduct an individual patient pooled analysis of the data from these published clinical trials. Patients and Methods Individual patient data were collected from the various study investigators who published their study results between 2000 and 2007. Between-study heterogeneity for study characteristics and patient populations was tested via χ2 tests before a pooled analysis. The primary end point, the change in hot flash activity from baseline to week 4, for each agent was calculated via both weighted and unweighted approaches, using the size of the study as the weight. Basic summary statistics were produced for hot flash score and frequency using the following three statistics: raw change, percent reduction, and whether or not a 50% reduction was achieved. Results This study included seven trials of newer antidepressants and three trials of gabapentin. The optimal doses (defined by individual study results) of the newer antidepressants paroxetine, venlafaxine, fluoxetine, and sertraline decreased hot flash scores by 41%, 33%, 13%, and 3% to 18% compared with the corresponding placebo arms, respectively. The three gabapentin trials decreased hot flashes by 35% to 38% compared with the corresponding placebo arms. Conclusion Some newer antidepressants and gabapentin, within 4 weeks of therapy initiation, decrease hot flashes more than placebo.
Maggot Débridement Therapy
Schwarck, Laurie

Mayo Clinic

The Journal of Continuing Education in Nursing | March 11, 2009 | Volume: 40 | Issue: 1 | Pages: 14-15

10.3928/00220124-20090101-04 | PMID 19226993 Get It

Due to rising health care costs and resistance to antibiotics, maggot débridement therapy may regain popularity. Nurses must learn about this unusual therapy and be prepared to assist patients who want to try it. J Contin Educ Nurs 2009;40(1):14–15.